Deutsche Bank initiated coverage of Merck with a Buy rating and $115 price target. The company’s Keytruda has established itself as backbone for oncology treatment regimens, which provides the best visibility for growth until fiscal 2028, barring GLP-1 peers, the analyst tells investors in a research note. The firm thinks the drug fundamentally sets Merck’s floor at $95 per share and gives a favorable asymmetric risk/reward for the company’s emerging pipeline.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on MRK:
- Portage Biotech presents updates on its iNKT, adenosine programs at SITC
- Actinium Pharmaceuticals names Lynn Bodarky as Chief Business Officer
- Merck price target raised to $135 from $130 at Citi
- Merck: FDA approves Keytruda in combination with gemcitabine and cisplatin
- Merck reports KEYNOTE-564 trial met its key overall survival secondary endpoint